CellMaxLife, University Gastroenterology & more: 3 GI company key notes

Here are three updates on gastroenterology companies to note:

CellMax Life's blood-based cancer detecting test can detect adenomas with close to 90 percent accuracy and cancer at 95 percent accuracy.

Eric Berthiaume, MD, was named Providence, R.I.-based University Gastroenterology's president.

Exelixis' cabozantinib was approved for use in patients with liver cancer. The drug was already approved for thyroid and renal cancer patients.

More articles on gastronerology:
FDA expands Cabozantinib approval to include liver cancer — 4 insights
5 experts weigh in on new GI-focused practice management companies & their implications
Blood-based CRC test detects adenomas with 90% accuracy — 4 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months